Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | CureCloud: liquid biopsy sequencing for multiple myeloma

Irene Ghobrial • 16 Dec 2020
ASH 2020
Multiple Myeloma
MMRF CureCloud

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the direct-to-patient Multiple Myeloma Research Foundation (MMRF) CureCloud Research Initiative. This study has developed a clinical-grade next-generation liquid biopsy sequencing platform, which allows for minimally invasive monitoring of multiple myeloma from home. Genomic reports are provided to the patients through the CureCloud platform and can be used for clinical care and trial identification. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals